10月23日,上海医药(601607/02607)发布公告,公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估,决定终止I025-A研发项目。 I025-A是靶向HER2的酪氨酸激酶抑制剂(TKI),拟用于晚期实体瘤的治疗。2021年7月,该项目获国家药品监督管理局批准开展临床试验。目前结直肠癌适应症处于II期临床试验结束阶段, HER2阳性晚期乳腺癌适应症1处于I期...
Source Link10月23日,上海医药(601607/02607)发布公告,公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估,决定终止I025-A研发项目。 I025-A是靶向HER2的酪氨酸激酶抑制剂(TKI),拟用于晚期实体瘤的治疗。2021年7月,该项目获国家药品监督管理局批准开展临床试验。目前结直肠癌适应症处于II期临床试验结束阶段, HER2阳性晚期乳腺癌适应症1处于I期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.